- Menarini Diagnostics to distribute Unyvero Platform and application cartridges in numerous European countries
- Menarini Diagnostics to deploy its commercial team for the marketing of Unyvero Platform across Europe
- Partnership to be launched at ECCMID 2019 in Amsterdam
Amsterdam, the Netherlands, and Holzgerlingen, Germany, March 26, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it has entered into an exclusive long-term strategic distribution partnership with A. Menarini Diagnostics (“AMD”). Effective immediately, Curetis will transfer all of its previous direct selling markets (Germany, France, Benelux, UK, Switzerland) to AMD. Countries, which were previously covered by individual local distribution partners such as Italy, Spain and Portugal, will also be transferred from Q2-2019 onwards and will be exclusively covered by AMD going forward. As the first Scandinavian market, AMD will also start commercializing the Unyvero Platform in Sweden. While focusing initially on these eleven markets, the parties are discussing potential future expansions to additional international territories.
By way of this pan-European distribution partnership, the Curetis Unyvero Platform and all CE -IVD marked Unyvero Application Cartridges for rapid detection of pathogens and antimicrobial resistance markers will be exclusively marketed and sold by AMD through AMD’s various national country organizations. AMD will dedicate its combined sales, customer service, marketing, scientific affairs and operations support team staff across these eleven markets for the commercialization of Curetis’ Unyvero product line. The parties expect that AMD’s commercial organization and infrastructure will greatly facilitate the further market adoption of the Unyvero Platform across Europe. Curetis will support AMD through its highly experienced commercial partner support team with a core of experts including product managers, tactical marketing experts, clinical application specialists and customer service and sales support specialists. All active commercial customer accounts as well as potential future customer accounts at various stages of evaluation of Unyvero in the partnered geographies will be transferred to AMD, effective immediately. AMD will manage the entire existing installed base of Unyvero Analyzers across the eleven markets and optimize the utilization of Application Cartridges on such installed base. Beyond the current installed base, AMD expects to drive new commercial account conversions and further Unyvero installations throughout these European markets.
“We are excited to partner with Curetis for the commercialization of the Unyvero Platform for rapid detection of pathogens and antimicrobial resistance markers for life-threatening infectious diseases in hospitalized patients across many key European markets. We see this easy-to-use sample-to-answer platform as an important opportunity to improve our molecular diagnostic franchise and further strengthen the commitment of the Menarini Group in the infectious disease area and the fight against life-threatening bacterial diseases following recent significant deals in the anti-infectives portfolio,” said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics.
“Entering into this strategic commercial distribution partnership for our flagship Unyvero A50 Platform and all CE-marked cartridges forms a key element of our new corporate strategy that we have outlined in December 2018,” stated Oliver Schacht, CEO of Curetis N.V. “With Menarini Diagnostics as our partner we will see more commercial resources being deployed behind Unyvero than would have been possible with Curetis´ own resources in many countries,” he added.
Curetis and Menarini Diagnostics aim to launch the collaboration at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the key event for clinical microbiology in Europe, which will take place in Amsterdam, The Netherlands, from April 13-19, 2019. Curetis will host a team of AMD representatives at the Curetis booth to jointly present the Unyvero Platform and its portfolio of application cartridges for severe infections in hospitalized patients to the visitors of the exhibition. Details of the launch event at ECCMID 2019 will be announced in due course ahead of the meeting.
The parties are also exploring several ways to further expand their collaboration in the future. To this end, they have entered a 90-day period of exclusive negotiations in the field of oncology in certain key territories (such as Europe, Middle East and Africa) for a license to Curetis’ Unyvero A30 RQ Platform, which is currently in development.
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.
About A. Menarini Diagnostics
Menarini Diagnostics belongs to the Menarini Pharmaceutical Group, which was founded in 1886. Today it’s present in 136 countries throughout the world, it counts 17,632 employees and has a 2018 turnover of € 3.6 billion.
For further information, please visit https://www.menarinidiagnostics.com/en-us
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
email@example.com or firstname.lastname@example.org
Curetis International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
A. Menarini Diagnostics S.r.l.
Via Lungo l’Ema, 7
Loc. Ponte a Ema
50012 Bagno a Ripoli (Florence) – Italy
Tel.: + 39 – 055-56801